Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin

Diabetes, Obesity and Metabolism

Volumn 18, Issue 7, 2016, Pages 654-662

  Nunez, Derek J ^a,b   Yao, X ^c   Lin, J ^d   Walker, A ^a,b   Zuo, P ^e   Webster, L ^f   Krug Gourley, S ^a,b   Zamek Gliszczynski, M J ^a,b   Gillmor, D S ^g   Johnson, S L ^h  

^a GLAXOSMITHKLINE   (United States)

^b Alexion Pharmaceuticals Inc ^*  (United States)

^c ALEXION PHARMACEUTICALS   (United States)

^d Grifols Therapeutics Inc   (United States)

^e PAREXEL INTERNATIONAL   (United States)

^f Nuventra Pharma Sciences   (United States)

^g Pharmaceutical Product Development   (United States)

^h PFIZER INC   (United States)

Author keywords

antidiabetic drug; drug mechanism; lipid lowering therapy; metformin; phase I II study; type 2 diabetes

Indexed keywords

7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CHOLEST 4 EN 3 ONE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GSK 2330672; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 3-((((3R,5R)-3-BUTYL-3-ETHYL-7-(METHYLOXY)-1,1-DIOXIDO-5-PHENYL-2,3,4,5-TETRAHYDRO-1,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)PENTANEDIOIC ACID; COTRANSPORTER; GLUCOSE BLOOD LEVEL; METHYLAMINE; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER; THIAZEPINE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL FECES COMPOSITION; ABRASION; ADULT; ANUS INJURY; AREA UNDER THE CURVE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HEMORRHOID; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PROCTALGIA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG ADMINISTRATION; DRUG EFFECTS; GASTROINTESTINAL DISEASE; LIPID METABOLISM; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; APOLIPOPROTEINS B; AREA UNDER CURVE; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; MALE; METFORMIN; METHYLAMINES; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; SYMPORTERS; THIAZEPINES; TREATMENT OUTCOME;

EID: 84964335814     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12656     Document Type: Article

References (30)

1. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012; 53: 1723–1737.
2. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167–177.
3. Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev 2013; 2: 213–222.
4. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50: 1955–1966.
5. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50: 2340–2357.
6. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2010; 49: 171–185.
7. Wu Y, Aquino CJ, Cowan DJ et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem 2013; 56: 5094–5114.
8. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998; 15: 651–656.
9. Napolitano A, Miller S, Nicholls AW et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 2014; 9: e100778.
10. International Conference on Harmonisation (ICH). Harmonised tripartite guideline. Guideline for good clinical practice, Version 10, 1996.
11. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043–3045.
12. Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991; 284: 216–218.
13. Dmitrienko A, Wang MD. Bayesian predictive approach to interim monitoring in clinical trials. Stat Med 2006; 25: 2178–2195.
14. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32: 73–79.
15. Svedlund J, Sjodin I, Dotevall G. GSRS–a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129–134.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
17. Martin SS, Blaha MJ, Elshazly MB et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013; 62: 732–739.
18. Galman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 1445–1453.
19. Kovar J, Lenicek M, Zimolova M, Vitek L, Jirsa M, Pitha J. Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects. Physiol Res 2010; 59: 233–238.
20. Steiner C, Othman A, Saely CH et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 2011; 6: e25006.
21. Galman C, Angelin B, Rudling M. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med 2011; 270: 580–588.
22. Bays HE. Colesevelam hydrochloride added to background metformin therapy in patients with type 2 diabetes mellitus: a pooled analysis from 3 clinical studies. Endocr Pract 2011; 17: 933–938.
23. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31: 1473–1478.
24. Beysen C, Murphy EJ, Deines K et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012; 55: 432–442.
25. Brufau G, Stellaard F, Prado K et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455–1464.
26. Sachdev S, Wang Q, Billington C et al. FGF 19 and bile acids increase following Roux-en-Y gastric bypass but not after medical management in patients with type 2 diabetes. Obes Surg 2015; DOI: 10.1007/s11695-015-1834-0 [Epub 11 August 2015].
27. Appleby RN, Walters JR. The role of bile acids in functional GI disorders. Neurogastroenterol Motil 2014; 26: 1057–1069.
28. Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs 2013; 22: 277–284.
29. Singhal R, Harrill AH, Menguy-Vacheron F, Jayyosi Z, Benzerdjeb H, Watkins PB. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol 2014; 15: 42.
30. Engelking LR, Gronwall R, Anwer MS. Effect of dehydrocholic, chenodeoxycholic, and taurocholic acids on the excretion of bilirubin. Am J Vet Res 1980; 41: 355–361.